ClinicalTrials.gov
public full text
Public Domain
CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Enhancing regulatory T cell therapy with gene editing / Viktor Glaser#1038086
- Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia : current perspectives, future challenges, and clinical implications#187918
- CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and … — Vertex Pharmaceuticals Incorporated (US20250041349A1)#653949
- Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation#1170359
- Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers#917873
Record · ID 127613
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive